Metsera said its drug’s half-life of 19 days supports once-monthly dosing. That would be an advantage over the once-weekly dosing of the GLP-1 drugs currently available and the clinical-stage ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of ...

MET-097i is Metsera’s fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i’s Phase 1/2 clinical trial in two presentations ...

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other ...

Metsera’s GLP-1 drug candidate could also support monthly dosing. And, with the molecules’ exposure profiles lining up, the biotech believes a once-monthly combination is viable.

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its ...

NEW YORK - Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company valued at $2.89 billion, today revealed positive topline results from its Phase 1 clinical trial for MET-233i ...

Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for ...

Cantor Fitzgerald reiterated an Overweight rating on Metsera Inc (NASDAQ: MTSR) following promising results from the company’s MET-233i obesity treatment.The research firm maintained its bullish ...

Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Jono Emmett ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.